1.800.KIDS DOC | 1.800.543.7362

Fei Chu, MD, PhD

Fei Chu, MD, PhD

Research Assistant Professor of Surgery, Northwestern University Feinberg School of Medicine

Education & Training

Education: Henderson State University, Arkadelphia, AR, 1992,

Postgraduate Training: Beijing Medical University, Beijing, China, Pathology, 1998

Research

Research Interests: Aging; cancer biology; metabolism; molecular biology; pediatrics; stem cells

Publications

Most recent publications

Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma J Pediatr Surg49 (6): 981-4
The role of nerve growth factor in caspase-dependent apoptosis in human BE(2)C neuroblastoma J Pediatr Surg46 (6): 1191-6
The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma PLoS One7 (7): e40816
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism Am J Physiol Cell Physiol296 (1): C65-74
Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent Angiogenesis11 (3): 269-76
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma J Pediatr Surg47 (6): 1267-71
Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy Biochim Biophys Acta1783 (12): 2294-300
Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics Cell Death Dis4e740
Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway Aging Cell7 (4): 516-25
Mesenchymal change and drug resistance in neuroblastoma J Surg Res193 (1): 279-88

Call 1.800.543.7362 for Insurance information. 1.800.543.7362